ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2022

Jan 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2022-01-03

Reporting Person: De Backer Marianne (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-03	Common Stock	S	2244	$64.25	Disposed	19256	Direct
2022-01-03	Common Stock	S	1984	$65.01	Disposed	17272	Direct
2022-01-03	Common Stock	S	272	$66.25	Disposed	17000	Direct

Footnotes

F1: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to
$64.69, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead
Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares
sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.73 to $65.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.